How To Determine How Young Women With Breast Cancer Treat It

Size: px
Start display at page:

Download "How To Determine How Young Women With Breast Cancer Treat It"

Transcription

1 Original Article Breast Cancer Presentation and Diagnostic Delays in Young Women Kathryn J. Ruddy, MD, MPH 1 ; Shari Gelber, MS, MSW 1 ; Rulla M. Tamimi, ScD 2 ; Lidia Schapira, MD 3 ; Steven E. Come, MD 4 ; Meghan E. Meyer, BS 1 ; Eric P. Winer, MD 1 ; and Ann H. Partridge, MD, MPH 1 BACKGROUND: Young women may experience delays in diagnosis of breast cancer, and these delays may contribute to poorer outcomes. METHODS: In a prospective, multicenter cohort study, women recently diagnosed with breast cancer at age 40 years were surveyed regarding their initial signs or symptoms of cancer and delays in diagnosis. Self delay was defined as 90 days between the first sign or symptom and a patient s first visit to consult a health care provider. Care delay was defined as 90 days between that first visit and the diagnosis of breast cancer. In a medical record review, tumor characteristics were assessed, including disease stage. Univariate and multivariate models were used to assess for predictors of self delay, care delay, and advanced stage in the selfdetected subset. RESULTS: In 585 eligible participants, the first sign or symptom of cancer was a self-detected breast abnormality for 80%, a clinical breast examination abnormality for 6%, an imaging abnormality for 12%, and a systemic symptom for 1%. Among women with self-detected cancers, 17% reported a self delay, and 12% reported a care delay. Self delays were associated with poorer financial status (P ). Among young women with self-detected breast cancers, care delay was associated at trend level (P 5.06) with higher stage in multivariate modeling. CONCLUSIONS: Most young women detect their own breast cancers, and most do not experience long delays before diagnosis. Women with fewer financial resources are more likely to delay seeking medical attention for a self-detected breast abnormality. Cancer 2014;120:20-5. VC 2013 American Cancer Society. KEYWORDS: breast neoplasms, early detection of cancer, breast self-examination, neoplasm metastasis, psychosocial factors. INTRODUCTION Breast cancer is diagnosed in fewer than 1 in 200 women aged 40 years in the United States, yet it is the leading cause of cancer-related deaths in this age group. 1 Breast cancers in young women are more likely to be large and lymph nodepositive at diagnosis, and younger women have an increased risk of recurrence and death from breast cancer compared with older women. 2,3 These variations may be explained by biologic differences, although delays in diagnosis also may contribute to presentation with more advanced stage disease and, thus, have an impact on prognosis. Data are limited regarding diagnostic delays and their possible contributions to outcome. 4,5 In an analysis of patient-reported data from a national sample of patients with cancer in the United Kingdom, younger and unmarried women with breast cancer experienced longer delays than older women. 4 A recent evaluation within the National Comprehensive Cancer Network Breast Cancer Outcomes Database Project revealed that women diagnosed with breast cancer at age 40 years were more likely to have diagnostic delays. Further analysis suggested that symptomatic presentation (ie, with a lump instead of a mammographic abnormality), which was more common in young women, was strongly associated with delays. 5 Data on the impact of delays in diagnosis on breast cancer outcomes are mixed. In a meta-analysis by Richards and colleagues of >25,000 women, those who experienced a delay of at least 3 months between the onset of symptoms and treatment for breast cancer were 12% less likely to be alive 5 years later. 6 In a more recent study, Love and colleagues did not observe shorter survival in Asian women who experienced a delay of greater than 6 months between finding a lump and being diagnosed with breast cancer, but they did report that women who experienced the longer delays had larger and more lymph node-positive tumors than those who did not. 7 In a large, prospective cohort study, we sought to evaluate how young women present with breast cancer, the frequency of delay in diagnosis, the factors associated with delays, and the relationship between delays and disease stage in patient-detected cancers. This work is based on 2 related models: 1) a psychosocial model that assumes that certain psychosocial and clinical factors could predispose some young women to Corresponding author: Kathryn J. Ruddy, MD MPH, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215; Fax: (617) ; katieruddy@gmail.com 1 Dana-Farber Cancer Institute, Boston, Massachusetts; 2 Channing Division of Network Medicine, Brigham and Women s Hospital, Boston, Massachusetts; 3 Medical Oncology, Massachusetts General Hospital, Boston, Massachusetts; 4 Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts DOI: /cncr.28287, Received: March 7, 2013; Revised: May 28, 2013; Accepted: July 1, 2013, Published online November 11, 2013 in Wiley Online Library (wileyonlinelibrary.com) 20 Cancer January 1, 2014

2 Breast Ca Presentation in Young Women/Ruddy et al delay seeking medical care for signs or symptoms of breast cancer or to experience a delay between their initial visit to a health care provider and receipt of a breast cancer diagnosis, and 2) a biologic model that assumes that delays could allow more time for cancers to grow and spread before diagnosis, potentially adversely affecting prognosis. MATERIALS AND METHODS We used patient-reported data from a multicenter, prospective cohort of women who were diagnosed with breast cancer at age 40 years. We studied the methods of breast cancer detection and the delays in seeking medical attention and subsequent diagnosis. Women were enrolled from 11 sites in Massachusetts and from 1 site in Denver, Colorado, into a prospective cohort study: The Young Women s Breast Cancer Study (available at: clinicaltrials.gov=ct2=show=nct , accessed July 23, 2013). Eligibility requirements included age 40 years and a diagnosis of stage I through IV breast cancer less than 6 months before enrollment. Surveys were mailed to all enrollees, and only those who responded within 9 months of diagnosis were included. These methods were detailed in a previous publication. 8 We evaluated initial signs or symptoms of cancer. The initial sign or symptom of cancer was categorized as either selfdetected (ie, the patient or a family member=friend detected a lump, nipple change, or other breast abnormality), exam-detected (ie, a health care provider detected an abnormality), imaging-detected (ie, a mammogram, breast magnetic resonance image, or other imaging test indicated an abnormality), or detected based on systemic symptoms (eg, weight loss or fatigue). We focused our analysis on patients who had selfdetected tumors to minimize bias in the results and because opportunities for future delay-reducing interventions may be greatest in this group. Among those who had self-detected cancers, we separately analyzed delays of at least 90 days either between the first sign or symptom and seeking medical attention (defined as self delay ) or between seeking medical attention and receiving a diagnosis of breast cancer (defined as care delay ). We used a 90-day definition for delays based on published research supporting a possible clinical relevance of this time period. 6,7 To assess our psychosocial model, univariate models were used to explore differences between women with and without delays of at least 90 days in either timeframe with regard to the following variables: age at diagnosis, college education, employment (fulltime vs not), married or living as married (vs not), finances (more vs less financially comfortable according to the measure described below), first-degree relative with breast or ovarian cancer (vs none), previous pregnancy (vs never pregnant), race (white vs other), and pregnancy at diagnosis (vs no pregnancy at diagnosis). Financial status was determined with the following measure: How would you describe your household s financial situation right now? (please circle only 1): 1. After paying the bills, you still have enough money for special things that you want. 2. You have enough money to pay the bills, but little spare money to buy extra or special things. 3. You have money to pay the bills, but only because you cut back on things. 4. You are having difficulty paying the bills, no matter what you do. Responses were dichotomized for analysis; participants were characterized as more financially comfortable if they chose the first answer and as less financially comfortable if they chose the second, third, or fourth answer. Those factors that were significant at the P <.20 level were tested in multivariate models. To assess our biologic model, univariate and multivariate logistic regression models also were used to evaluate associations between stage IV disease (vs stage I-III disease) and the following variables: self delay, care delay, age at diagnosis, college education, employment (fulltime vs not), married or living as married (vs not), finances ( money for special things vs not), first-degree relative with breast or ovarian cancer (vs none), previous pregnancy (vs never pregnant), race (white vs other), pregnancy at diagnosis (vs no pregnancy at diagnosis), grade (1/2 v 3), estrogen receptor status, progesterone receptor status, and human epidermal growth factor receptor [Her2] status. In a secondary analysis, we excluded women for whom self delay or care delay was 365 days (n 5 17) to evaluate the impact of the outliers on the analysis of predictors of delays in women with self-detected cancers. RESULTS Between November 1, 2006 and October 31, 2012, 1408 women were invited to participate in a cohort study, and 843 women (60%) enrolled. Seven hundred twenty women had completed at least part of the baseline survey at the time of this analysis. Forty-three women were excluded from the current analysis because they had stage 0 disease, 49 were excluded because their stage information was not available at the time of analysis, and 43 were excluded because they did not answer both questions regarding delays in diagnosis. There were 585 remaining Cancer January 1,

3 Original Article TABLE 1. Presentation of Breast Cancer in Young Women Primary Method of Cancer Detection No. of Patients (%) Self-detected 470 (80) Exam-detected 33 (6) Imaging-detected, eg, by mammogram or MRI 68 (12) Detected based on systemic symptoms 7 (1) Missing 7 (1) Abbreviations: MRI, magnetic resonance imaging. TABLE 2. Patient and Tumor Characteristics Characteristic Total, N No. of Patients (%) Self-Detected, N Patient characteristics Age: Median [range], y 37 [17-40] 36 [17-40] White 518 (89) 416 (89) College educated 484 (83) 389 (83) Pregnant at diagnosis 25 (4) 24 (5) Never pregnant before diagnosis 164 (28) 132 (28) Employed fulltime 253 (43) 205 (44) Married or living as married 441 (75) 348 (74) Financially comfortable 286 (49) 225 (48) Medically insured 584 (99) 469 (99) First-degree relative with 78 (13) 56 (12) breast or ovarian cancer Tumor characteristics Disease stage I 210 (36) 147 (31) II 258 (44) 226 (48) III 80 (14) 73 (16) IV 37 (6) 24 (5) Tumor grade 1 37 (6) 21 (4) (32) 142 (30) (61) 303 (64) Missing 5 (1) 4 (1) ER positive 399 (68) 302 (64) ER missing 1 (0.2) 1 (0.2) PR positive 359 (61) 265 (56) PR missing 1 (0.2) 1 (0.2) Her2 positive 185 (32) 149 (32) Her2 missing 5 (1) 3 (0.6) Abbreviations: ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; PR, progesterone receptor. eligible participants. Four hundred seventy women (80%) reported that the first evidence of their breast cancer was a self-detected breast abnormality. Fewer women reported that the first evidence of their cancer appeared during a clinical breast examination (6%), on a mammogram or magnetic resonance image (12%), or as a systemic symptom (1%) (see Table 1). Table 2 presents patient and tumor characteristics for the entire cohort and for those who had self-detected cancers. The median age at diagnosis was 37 years (range, years). In those who selfdetected their cancers, the median time between the initial sign and seeking medical attention was 14 days (25th to TABLE 3. Delays Among Women With Self- Detected Cancers Delay Delay from noticing symptom to seeking care from a health care provider Delay from seeing health care provider to receiving diagnosis Delay Total No. of Patients Responding Median Delay [25th to 75th percentile], d [3-45] [7-30] Total No. No. With Delay (%) of Patients (17) Delay 90 d to medical attention: Self delay Delay 90 d to diagnosis: (12) Care delay Self delay 90 d and (3) care delay 90 d Delay 180 d to medical attention (7) Delay 180 d to diagnosis (6) Delay 365 d to medical attention (2) Delay 365 d to diagnosis (2) 75th percentile, 3-45 days). Seventeen percent of women with self-detected cancers recalled self delay between the initial sign and medical attention. The median time between seeking medical attention and diagnosis was 16.5 days (25th to 75th percentile, 7-30 days). Twelve percent of women with self-detected cancers recalled care delay. Three percent of women with self-detected cancers recalled self delay and care delay (for data regarding the timing of cancer presentation and diagnosis, see Table 3). In univariate and multivariate modeling among patients with self-detected cancers, those who were less financially comfortable (ie, did not have money for special things ) were more likely to experience self delay (univariate odds ratio [OR], 2.08; 95% confidence interval [CI], ; P 5.005; multivariate OR, 2.0; 95% CI, P 5.01). In those who had a first-degree relative with breast or ovarian cancer, there was also a trend toward less self delay (univariate OR, 0.39, 95% CI, ; P 5.08; multivariate OR, 0.39; 95% CI, ; P 5.08). College education also met criteria for inclusion in the multivariate model for self delay based on a P value.2 (univariate OR, 0.63; 95% CI, ; P 5.14), but this was not significant in the multivariate model (multivariate OR, 0.76; 95% CI, ; P 5.39). Multivariate regression revealed that patients with self-detected cancers who had a first-degree relative with breast or ovarian cancer were more likely to report care delay (OR, 2.76; 95% CI, ; P 5.005). Other covariates that met criteria for inclusion in the multivariate model for care delay based on a P value.2 in 22 Cancer January 1, 2014

4 Breast Ca Presentation in Young Women/Ruddy et al TABLE 4. Relationships Between Delays and Characteristics Among Women With Self-Detected Cancers No. of Patients P No. of Patients P Characteristic Self Delay, N 5 77 No Self Delay, N Univariate Multivariate Care Delay, N 5 57 No Care Delay, N Univariate Multivariate Age: Median (range), y 36 (22-40) 37 (17-40) (17-40) 36 (22-40) Race White Other Education College <College Pregnant at diagnosis -.53 Yes No Ever pregnant Yes No Employment Full time Less than full time Marital status Married or living as married Other Financial status Financially comfortable Not financially comfortable Family history First-degree relative with breast or ovarian cancer No first-degree relative with breast or ovarian cancer univariate models, but that were not significant in multivariate analysis, included age at diagnosis and race (see Table 4 for models). Although univariate modeling suggested a possible association between stage IV disease and self delay, care delay, financial discomfort, and positive Her2 status, none of those variables reached statistical significance in multivariate modeling (see Table 5). However, there was a possible, statistically nonsignificant (P 5.06) link between care delays and disease stage. When we restricted the analysis (data not shown) to include only women who did not have a self delay 365 days (N 5 7) or a care delay 365 days (N 5 10), the results were similar, indicating that data from outliers were not driving the findings. DISCUSSION Breast cancer is the leading cause of cancer-related death in young women. 9 Although prior studies have raised concern that delays in diagnosis may be responsible for poorer prognoses in younger patients, our study indicates that most young women do not experience long delays after they detect a breast abnormality themselves. Our study confirms that the vast majority of women who are diagnosed with breast cancer at age 40 years detect their own breast abnormalities, which is consistent with data from prior studies and with the lack of effective routine breast cancer screening for young women. 10 We observed that some women with self-detected cancers experienced delays of at least 90 days either before they sought medical attention for a symptom (self delay) or between the time of first consultation with a health care professional and receiving the diagnosis of breast cancer (care delay). These delays may result from inadequate awareness of the disease or low suspicion for malignancy among both patients and health care professionals. In our study population, women who were less financially comfortable were more likely to experience delays in seeking medical attention. This suggests an economic disparity that deserves further attention and supports our psychosocial model. It is possible that copays and hidden costs of seeking medical care (eg, parking charges, child-care expenses, lost wages) may be obstacles to timely evaluation of a new symptom for women who Cancer January 1,

5 Original Article TABLE 5. Relationships Between Disease Stage and Patient/Tumor Characteristics in Women With Self-Detected Cancers No. of Patients P Characteristic Stage I-III, N Stage IV, N 5 24 Univariate Multivariate Age: Median (range), y 36 (17-40) 36.5 (23-40).68 Self delay Yes 70 7 No Care delay Yes 51 6 No Race.76 Caucasian Other 45 2 Education.58 College <College 73 5 Pregnant at Dx.81 Yes 23 1 No Ever pregnant.30 Yes No Employment.30 Full time Less than full time Marital status.37 Married Other Financial status Financially comfortable Other Family history - Yes 56 0 No Grade.98 1 or ER status.81 Positive Negative PR status.28 Positive Negative Her2 status Positive Negative Abbreviations: Dx, diagnosis; ER, estrogen receptor; Her2, human epidermal growth factor receptor 2; PR, progesterone receptor. feel financially insecure. Although we recognize that tumor subtype may have an impact on clinical presentation, 11 we chose not to include tumor features like estrogen receptor status, progesterone receptor status, Her2 status, and tumor grade in our models for delays because we were seeking to identify characteristics that would allow targeted prediagnostic interventions to reduce delays in the future. Counter to expectations, we observed that a family history of breast or ovarian cancer predicted a higher likelihood of care delay. Although a relevant family history would be expected to trigger more rapid evaluation and diagnosis of a self-detected breast complaint, the opposite was reported by women in this study. This finding may be spurious, or it could be the result of recall bias in a population that may have more baseline anxiety based on lived experience and family history. Another explanation is that some women who have first-degree relatives with breast or ovarian cancer may be hypervigilant, presenting so quickly for medical attention that clinicians wait for a few menstrual cycles before they perform definitive diagnostic testing. Additional research is needed to explore the 24 Cancer January 1, 2014

6 Breast Ca Presentation in Young Women/Ruddy et al potential relationship between family history and diagnostic delays. Our finding that higher stage may be associated with care delay at trend level (P 5.06) supports the hypothesis (founded on a biologic model) that diagnostic delays may contribute to higher stage and, thus, potentially may have an impact on outcomes in young patients. Delays of at least 180 or 365 days were very rare (too rare to allow statistical testing for associations with stage in this study), but it is possible that women who experience these longer delays are the most detrimentally affected. Because we did not evaluate breast cancer recurrence or survival rates in the current study, it remains unclear whether delays contribute substantially to the poorer prognoses of young women overall, which may be driven more by tumor and host biology Limitations of this work include that we did not prospectively collect data regarding reasons for delays and that delay data relied solely on patient self-report. Because the vast majority of our study population was white, highly educated, married or living as married, and insured, it is possible that a lack of diversity prevented identification of other sociodemographic factors that predispose young women to delays in the general population. Our findings are also limited by multiple testing with no adjustments for nominal P values and by recall bias (ie, participants may be inaccurate in their reporting of delays). Our findings may not be generalizable because this multicenter cohort study identified participants by pathology review at participating sites and was not population-based; furthermore, because participation was strictly voluntary, our sample may not be representative of the population at large. Future research is needed to investigate whether delays can be reduced by: 1) educating young women about the importance of seeking prompt medical attention for new breast abnormalities and 2) increasing awareness in the medical community of appropriate evaluation and follow-up for breast abnormalities in young women. If education of young women and=or health care providers about the signs and symptoms of breast cancer facilitates more rapid diagnosis and treatment, more cancers might be excised before they metastasize outside the breast, possibly resulting in fewer deaths. Relevant interventions may be most effective if they are targeted at young women who are less financially comfortable and, thus, are more at risk of a delay in seeking medical attention. FUNDING SUPPORT This study was supported by a grant from Susan G. Komen for the Cure (Ann H. Partridge, principal investigator). CONFLICT OF INTEREST DISCLOSURES The authors made no disclosures. REFERENCES 1. American Cancer Society. Breast Cancer Facts and Figures Atlanta, GA: American Cancer Society; Zabicki K, Colbert JA, Dominguez FJ, et al. Breast cancer diagnosis in women 40 versus 50 to 60 years: increasing size and stage disparity compared with older women over time. Ann Surg Oncol. 2006;13: Ahn SH, Son BH, Kim SW, et al. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea a report from the Korean Breast Cancer Society. J Clin Oncol. 2007;25: Neal RD, Allgar VL. Sociodemographic factors and delays in the diagnosis of 6 cancers: analysis of data from the National Survey of NHS Patients: Cancer. Br J Cancer. 2005;92: Partridge AH, Hughes ME, Ottesen RA, et al. The effect of age on delay in diagnosis and stage of breast cancer. Oncologist. 2012;17: Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353: Love RR, Duc NB, Baumann LC, et al. Duration of signs and survival in premenopausal women with breast cancer. Breast Cancer Res Treat. 2004;86: Collins LC, Marotti JD, Gelber S, et al. Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer. Breast Cancer Res Treat. 2012;131: Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, CA Cancer J Clin. 2010;60: Foxcroft LM, Evans EB, Porter AJ. The diagnosis of breast cancer in women younger than 40. Breast. 2004;13: Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triplenegative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012;118: Keegan TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women [serial online]. Breast Cancer Res. 2012;14:R Colleoni M, Rotmensz N, Robertson C, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol. 2002;13: Colleoni M, Rotmensz N, Peruzzotti G, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17: Cancer January 1,

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?

Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.

More information

Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation

Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Travel Distance to Healthcare Centers is Associated with Advanced Colon Cancer at Presentation Yan Xing, MD, PhD, Ryaz B. Chagpar, MD, MS, Y Nancy You MD, MHSc, Yi Ju Chiang, MSPH, Barry W. Feig, MD, George

More information

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal

More information

Breast Cancer in Young Women: Quality of Life and Survivorship

Breast Cancer in Young Women: Quality of Life and Survivorship Breast Cancer in Young Women: Quality of Life and Survivorship Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Breast Cancer in Young Women is

More information

October is Breast Cancer Awareness Month!

October is Breast Cancer Awareness Month! October is Breast Cancer Awareness Month! A STUDY OF CHARACTERISTICS AND MANAGEMENT OF BREAST CANCER IN TAIWAN Eric Kam-Chuan Lau, OMS II a, Jim Yu, OMSII a, Christabel Moy, OMSII a, Jian Ming Chen, MD

More information

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER

GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic

More information

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2011 June 30, 2012 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for

More information

Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies

Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Breast Cancer Screening in Low- and Middle-Income Countries A Framework To Choose Screening Strategies Richard Wender, MD Session code: www.worldcancercongress.org A Five Step Framework to Guide Screening

More information

Nicole Kounalakis, MD

Nicole Kounalakis, MD Breast Disease: Diagnosis and Management Nicole Kounalakis, MD Assistant Professor of Surgery Goal of Breast Evaluation The goal of breast evaluation is to classify findings as: normal physiologic variations

More information

One of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.

One of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.

More information

Breast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA

Breast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for

More information

Effect of Anxiety or Depression on Cancer Screening among Hispanic Immigrants

Effect of Anxiety or Depression on Cancer Screening among Hispanic Immigrants Racial and Ethnic Disparities: Keeping Current Seminar Series Mental Health, Acculturation and Cancer Screening among Hispanics Wednesday, June 2nd from 12:00 1:00 pm Trustees Conference Room (Bulfinch

More information

Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up

Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study of a Large Dataset with a Long Term Follow-up Georgia State University ScholarWorks @ Georgia State University Mathematics Theses Department of Mathematics and Statistics 7-28-2012 Effect of Risk and Prognosis Factors on Breast Cancer Survival: Study

More information

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background:

1.0 Abstract. Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA. Keywords. Rationale and Background: 1.0 Abstract Title: Real Life Evaluation of Rheumatoid Arthritis in Canadians taking HUMIRA Keywords Rationale and Background: This abbreviated clinical study report is based on a clinical surveillance

More information

Religious and Spiritual Issues in African Americans at Increased Risk for Cancer

Religious and Spiritual Issues in African Americans at Increased Risk for Cancer Religious and Spiritual Issues in African Americans at Increased Risk for Cancer Chanita Hughes Halbert, Ph.D. Department of Psychiatry and Abramson Cancer Center Populations at Increased Risk for Developing

More information

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis Maura Iversen,, PT, DPT, SD, MPH 1,2,3 Ritu Chhabriya,, MSPT 4 Nancy Shadick, MD 2,3 1 Department of Physical Therapy, Northeastern

More information

Understanding ductal carcinoma in situ (DCIS) and deciding about treatment

Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding

More information

Metastatic Breast Cancer...

Metastatic Breast Cancer... DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a

More information

Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey

Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey Complementary and alternative medicine use in Chinese women with breast cancer: A Taiwanese survey Dr Fang-Ying (Sylvia) Chu Department of Nursing, Tzu Chi College of Technology, Hua Lien, Taiwan 1 BACKGROUND

More information

7. Prostate cancer in PSA relapse

7. Prostate cancer in PSA relapse 7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined

More information

The Impact of Palliative Care and Hospice Services in the Care of Patients with Advanced Stage Non-Small Cell Lung Cancer

The Impact of Palliative Care and Hospice Services in the Care of Patients with Advanced Stage Non-Small Cell Lung Cancer The Impact of Palliative Care and Hospice Services in the Care of Patients with Advanced Stage Non-Small Cell Lung Cancer Richard C. Stephenson, MD Hospice & Palliative CareCenter Amy H. Hughes Forsyth

More information

Abstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2

Abstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2 Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo

More information

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data

Analysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500

More information

How To Decide If You Should Get A Mammogram

How To Decide If You Should Get A Mammogram American Medical Women s Association Position Paper on Principals of Breast Cancer Screening Breast cancer affects one woman in eight in the United States and is the most common cancer diagnosed in women

More information

Breast Cancer Follow-Up

Breast Cancer Follow-Up Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Breast Cancer Follow-Up Breast Cancer Follow-Up Version 2002: Thomssen / Scharl Version 2003 2009: Bauerfeind / Bischoff /

More information

BRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide

BRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide BRCA1 & BRCA2: Genetic testing for hereditary breast and ovarian cancer patient guide What is Hereditary? Breast cancer is the most common cancer in women in the U.S. (it affects about 1 in 8 women). Ovarian

More information

How To Use A Breast Cancer Test To Help You Choose Chemotherapy

How To Use A Breast Cancer Test To Help You Choose Chemotherapy Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September

More information

2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older)

2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older) 2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older) IMPTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered satisfactory

More information

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University

Measures of Prognosis. Sukon Kanchanaraksa, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant

Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Oncology Nursing Society Annual Progress Report: 2008 Formula Grant Reporting Period July 1, 2009 June 30, 2010 Formula Grant Overview The Oncology Nursing Society received $12,473 in formula funds for

More information

Dealing with Missing Data

Dealing with Missing Data Dealing with Missing Data Roch Giorgi email: roch.giorgi@univ-amu.fr UMR 912 SESSTIM, Aix Marseille Université / INSERM / IRD, Marseille, France BioSTIC, APHM, Hôpital Timone, Marseille, France January

More information

Breast Cancer. Presentation by Dr Mafunga

Breast Cancer. Presentation by Dr Mafunga Breast Cancer Presentation by Dr Mafunga Breast cancer in the UK Breast cancer is the second most common cancer in women. Around 1 in 9 women will develop breast cancer It most commonly affects women over

More information

Understanding Your Risk of Ovarian Cancer

Understanding Your Risk of Ovarian Cancer Understanding Your Risk of Ovarian Cancer A WOMAN S GUIDE This brochure is made possible through partnership support from Project Hope for Ovarian Cancer Research and Education. Project HOPE FOR OVARIAN

More information

OBJECTIVES By the end of this segment, the community participant will be able to:

OBJECTIVES By the end of this segment, the community participant will be able to: Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway

More information

Colorectal Cancer Screening Behaviors among American Indians in the Midwest

Colorectal Cancer Screening Behaviors among American Indians in the Midwest JOURNAL OF HD RP Journal of Health Disparities Research and Practice Volume 4, Number 2, Fall 2010, pp. 35 40 2010 Center for Health Disparities Research School of Community Health Sciences University

More information

Adjuvant Therapy for Breast Cancer: Questions and Answers

Adjuvant Therapy for Breast Cancer: Questions and Answers CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast

More information

Evaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003

Evaluation and Management of the Breast Mass. Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Evaluation and Management of the Breast Mass Gary Dunnington,, M.D. Department of Surgery Internal Medicine Ambulatory Conference December 4, 2003 Common Presentations of Breast Disease Breast Mass Abnormal

More information

Kanıt: Klinik çalışmalarda ZYTIGA

Kanıt: Klinik çalışmalarda ZYTIGA mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen

More information

Breast Cancer Educational Program. June 5-6, 2015

Breast Cancer Educational Program. June 5-6, 2015 Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:

More information

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective

4/8/13. Pre-test Audience Response. Prostate Cancer 2012. Screening and Treatment of Prostate Cancer: The 2013 Perspective Pre-test Audience Response Screening and Treatment of Prostate Cancer: The 2013 Perspective 1. I do not offer routine PSA screening, and the USPSTF D recommendation will not change my practice. 2. In light

More information

Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125)

Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36125 Original ICD-9 LCD

More information

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University

Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin

More information

Disclosure. I have the following relationships with commercial interests:

Disclosure. I have the following relationships with commercial interests: Disclosure Electra Paskett, Ph.D., MPH I have the following relationships with commercial interests: Merck Research grant, in-kind donation Pfizer Stock ownership Meridian Bioscience Stock ownership A

More information

Drug/Drug Combination: Bevacizumab in combination with chemotherapy

Drug/Drug Combination: Bevacizumab in combination with chemotherapy AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy

More information

ductal carcinoma in situ (DCIS)

ductal carcinoma in situ (DCIS) Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre

More information

Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen

Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen VOLUME 22 NUMBER 3 FEBRUARY 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Are Patients Diagnosed With Breast Cancer Before Age 50 Years Ever Cured? Hermann Brenner and Timo Hakulinen

More information

Florida Breast Health Specialists Breast Cancer Information and Facts

Florida Breast Health Specialists Breast Cancer Information and Facts Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to

More information

Recommendations for the management of early breast cancer

Recommendations for the management of early breast cancer Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation FEBRUARY 2014 Incorporates published evidence to August

More information

Progress and Prospects in Ovarian Cancer Screening and Prevention

Progress and Prospects in Ovarian Cancer Screening and Prevention Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian

More information

BreastScreen and You. Information about mammographic screening

BreastScreen and You. Information about mammographic screening BreastScreen and You Information about mammographic screening This information is about screening for breast cancer. It aims to help you choose whether or not you take part in the BreastScreen Australia

More information

Breast Cancer Treatment Guidelines

Breast Cancer Treatment Guidelines Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision

More information

Electronic health records to study population health: opportunities and challenges

Electronic health records to study population health: opportunities and challenges Electronic health records to study population health: opportunities and challenges Caroline A. Thompson, PhD, MPH Assistant Professor of Epidemiology San Diego State University Caroline.Thompson@mail.sdsu.edu

More information

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS?

HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women

More information

Modeling Drivers of Cost and Benefit for Policy Development in Cancer

Modeling Drivers of Cost and Benefit for Policy Development in Cancer Modeling Drivers of Cost and Benefit for Policy Development in Cancer Harms? Benefits? Costs? Ruth Etzioni Fred Hutchinson Cancer Research Center Seattle, Washington The USPSTF recommends against routine

More information

RED, BOOST, and You: Improving the Discharge Transition of Care

RED, BOOST, and You: Improving the Discharge Transition of Care RED, BOOST, and You: Improving the Discharge Transition of Care Jeffrey L. Greenwald, MD, SFHM Massachusetts General Hospital - Clinician Educator Service Co-Investigator Project RED & Project BOOST The

More information

BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt

BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader. Two years ago, I was working as a bedside nurse. One of my colleagues felt Ali A. Kader, S. (2010). Breast cancer awareness for women and men. UCQ Nursing Journal of Academic Writing, Winter 2010, 70 76. BREAST CANCER AWARENESS FOR WOMEN AND MEN by Samar Ali A. Kader Two years

More information

Frequently Asked Questions About Ovarian Cancer

Frequently Asked Questions About Ovarian Cancer Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues

More information

Research Article Biological Characteristics and Medical Treatment of Breast Cancer in Young Women A Featured Population: Results from the NORA Study

Research Article Biological Characteristics and Medical Treatment of Breast Cancer in Young Women A Featured Population: Results from the NORA Study SAGE-Hindawi Access to Research International Journal of Breast Cancer Volume 2, Article ID 534256, 6 pages doi:.46/2/534256 Research Article Biological Characteristics and Medical Treatment of Breast

More information

Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update

Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Shannon Puhalla, MD Director, Breast Cancer Clinical Research Program Magee Womens Cancer Program University of Pittsburgh Cancer Institute Questions

More information

Breast Cancer Care & Research

Breast Cancer Care & Research Breast Cancer Care & Research Professor John FR Robertson University of Nottingham Nottingham City Hospital Breast Cancer (BC) 15,000 BC deaths in the UK each year 20% female cancer deaths 5% all female

More information

Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement

Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement Rebecca Ferrini, MD, Elizabeth Mannino, MD, Edith Ramsdell, MD and Linda Hill, MD, MPH Burden

More information

Appendices. 2006 Bexar County Community Health Assessment Appendices Appendix A 125

Appendices. 2006 Bexar County Community Health Assessment Appendices Appendix A 125 Appendices Appendix A Recent reports suggest that the number of mothers seeking dropped precipitously between 2004 and 2005. Tables 1A and 1B, below, shows information since 1990. The trend has been that

More information

Feeling Your Way To Healthy Breast. Lisa Barnes, BSN, RN Ruth Fay,B.A.,M.B.A.,RN Mary Grady, BSN, RN Margaret Richmond, MA, RN

Feeling Your Way To Healthy Breast. Lisa Barnes, BSN, RN Ruth Fay,B.A.,M.B.A.,RN Mary Grady, BSN, RN Margaret Richmond, MA, RN Feeling Your Way To Healthy Breast Lisa Barnes, BSN, RN Ruth Fay,B.A.,M.B.A.,RN Mary Grady, BSN, RN Margaret Richmond, MA, RN WHAT ARE MY BREASTS MADE OF? A breast is made of three main parts: glands,

More information

Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology; May 29 to June 2, 2009; Orlando, FL.

Presented in part at the 45th Annual Meeting of the American Society of Clinical Oncology; May 29 to June 2, 2009; Orlando, FL. Clinicopathologic Features, Patterns of Recurrence, and Survival Among Women With Triple-Negative Breast Cancer in the National Comprehensive Cancer Network Nancy U. Lin, MD 1 ; Ann Vanderplas, MS 2 ;

More information

Mode and Patient-mix Adjustment of the CAHPS Hospital Survey (HCAHPS)

Mode and Patient-mix Adjustment of the CAHPS Hospital Survey (HCAHPS) Mode and Patient-mix Adjustment of the CAHPS Hospital Survey (HCAHPS) April 30, 2008 Abstract A randomized Mode Experiment of 27,229 discharges from 45 hospitals was used to develop adjustments for the

More information

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer

Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line

More information

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015

Description of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015 Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer

More information

Guide to Understanding Breast Cancer

Guide to Understanding Breast Cancer An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients

More information

Cancer research in the Midland Region the prostate and bowel cancer projects

Cancer research in the Midland Region the prostate and bowel cancer projects Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate

More information

Phyllodes tumours: borderline malignant and malignant

Phyllodes tumours: borderline malignant and malignant Phyllodes tumours: borderline malignant and malignant This booklet is for people who would like more information on borderline malignant or malignant phyllodes tumours. It describes what they are, the

More information

Breast Cancer. CSC Cancer Experience Registry Member, breast cancer

Breast Cancer. CSC Cancer Experience Registry Member, breast cancer ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.

More information

Workplace Pension Reform: Multiple Jobholders

Workplace Pension Reform: Multiple Jobholders Workplace Pension Reform: Multiple Jobholders July 2013 1 Introduction The analysis presented in this paper is intended to support the passage of the 2013-14 Pensions Bill through Parliament. It provides

More information

Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194

Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194 Ductal Carcinoma In Situ Treated With Breast-Conserving Surgery and Radiotherapy: A Comparison With ECOG Study 5194 Sabin B. Motwani, MD 1 ; Sharad Goyal, MD 1 ; Meena S. Moran, MD 2 ; Arpit Chhabra, BS

More information

Frequency of NHL Subtypes in Adults

Frequency of NHL Subtypes in Adults Chemotherapy Options Stephanie A. Gregory, M.D. The Elodia Kehm Professor of Medicine Director, Section of Hematology Rush University Medical Center Chicago, Illinois Frequency of NHL Subtypes in Adults

More information

Follow-up care plan after treatment for breast cancer. A guide for General Practitioners

Follow-up care plan after treatment for breast cancer. A guide for General Practitioners Follow-up care plan after treatment for breast cancer A guide for General Practitioners This leaflet provides information for GPs on the follow-up care required by women who had breast cancer. It is for

More information

Does referral from an emergency department to an. alcohol treatment center reduce subsequent. emergency room visits in patients with alcohol

Does referral from an emergency department to an. alcohol treatment center reduce subsequent. emergency room visits in patients with alcohol Does referral from an emergency department to an alcohol treatment center reduce subsequent emergency room visits in patients with alcohol intoxication? Robert Sapien, MD Department of Emergency Medicine

More information

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic

More information

New Treatment Advances for Breast Cancer

New Treatment Advances for Breast Cancer New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center

More information

Breast Cancer Screening

Breast Cancer Screening Breast Cancer Screening The American Cancer Society and Congregational Health Ministry Team October Module To access this module via the Web, visit www.cancer.org and type in congregational health ministry

More information

East Midlands Cancer Clinical Network Improving Lung Cancer Outcomes. Dr Paul Beckett Royal Derby Hospital

East Midlands Cancer Clinical Network Improving Lung Cancer Outcomes. Dr Paul Beckett Royal Derby Hospital East Midlands Cancer Clinical Network Improving Lung Cancer Outcomes Dr Paul Beckett Royal Derby Hospital Number of resections Five year net survival Background to the Workshop Survival for lung cancer

More information

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.

Prognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D. Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or

More information

Breast Cancer Awareness Month

Breast Cancer Awareness Month Aon Kenya Insurance Brokers Ltd Aon Hewitt Healthcare Division Breast Cancer Awareness Month Issue 12 October 2015 In this Issue 2 Cancer Statistics in Kenya 3 What is Breast Cancer? 4 Symptoms of Breast

More information

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee

Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a

More information

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare

More information

Office of Population Health Genomics

Office of Population Health Genomics Office of Population Health Genomics Policy: Protocol for the management of female BRCA mutation carriers in Western Australia Purpose: Best Practice guidelines for the management of female BRCA mutation

More information

Imaging Markers of Brain Network Dysfunction in Multiple Sclerosis

Imaging Markers of Brain Network Dysfunction in Multiple Sclerosis Faculty of Medicine & Health Sciences School of Medicine Radiological Sciences Research Group The University of Nottinham University Park Nottingham NG7 2RD t: +44 (0)115 823 0018 f: +44 (0)115 823 0004

More information

Us TOO University Presents: Understanding Diagnostic Testing

Us TOO University Presents: Understanding Diagnostic Testing Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by

More information

Correlates of Referral Practices of General Surgeons to Plastic Surgeons for Mastectomy Reconstruction

Correlates of Referral Practices of General Surgeons to Plastic Surgeons for Mastectomy Reconstruction 1715 Correlates of Referral Practices of General Surgeons to Plastic Surgeons for Mastectomy Reconstruction Amy K. Alderman, MD, MPH 1,2 Sarah T. Hawley, PhD 2,3 Jennifer Waljee, MD 4 Monica Morrow, MD

More information

Views of Primary Care Providers on Follow-up Care of Cancer Patients

Views of Primary Care Providers on Follow-up Care of Cancer Patients Award-winning Research Papers From the 2006 AAFP Annual Scientific Assembly Vol. 39, No. 7 477 Views of Primary Care Providers on Follow-up Care of Cancer Patients Mary Jo Nissen, PhD, MPH; Mary Sue Beran,

More information

Pre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013

Pre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013 Objectives After completion of this presentation, the participant will be able to: Explain the current

More information

There are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all.

There are many different types of cancer and sometimes cancer is diagnosed when in fact you are not suffering from the disease at all. About Cancer Cancer is a disease where there is a disturbance in the normal pattern of cell replacement. The cells mutate and become abnormal or grow uncontrollably. Not all tumours are cancerous (i.e.

More information

Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan

Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan Caregiving Impact on Depressive Symptoms for Family Caregivers of Terminally Ill Cancer Patients in Taiwan Siew Tzuh Tang, RN, DNSc Associate Professor, School of Nursing Chang Gung University, Taiwan

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Mammograms & Breast Health. An Information Guide for Women U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention

Mammograms & Breast Health. An Information Guide for Women U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Mammograms & Breast Health An Information Guide for Women This booklet was developed by the Centers for Disease Control

More information

Ovarian Cancer Genetic Testing: Why, When, How?

Ovarian Cancer Genetic Testing: Why, When, How? Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine

More information

La personalizzazione terapeutica: quanto influisce l età

La personalizzazione terapeutica: quanto influisce l età La personalizzazione terapeutica: quanto influisce l età PierFranco Conte University of Padova Department of Surgery, Oncology and Gastroenterology IOV Istituto Oncologico Veneto I.R.C.C.S. Breast Cancer

More information

The PLCO Trial Not a comparison of Screening vs no Screening

The PLCO Trial Not a comparison of Screening vs no Screening PSA Screening: Science, Politics and Uncertainty David F. Penson, MD, MPH Hamilton and Howd Chair of Urologic Oncology Professor and Chair, Department of Urologic Surgery Director, Center for Surgical

More information

Multiple logistic regression analysis of cigarette use among high school students

Multiple logistic regression analysis of cigarette use among high school students Multiple logistic regression analysis of cigarette use among high school students ABSTRACT Joseph Adwere-Boamah Alliant International University A binary logistic regression analysis was performed to predict

More information

Ovarian Cancer. in Georgia, 1999-2003. Georgia Department of Human Resources Division of Public Health

Ovarian Cancer. in Georgia, 1999-2003. Georgia Department of Human Resources Division of Public Health Ovarian Cancer in Georgia, 1999-23 Georgia Department of Human Resources Division of Public Health Acknowledgments Georgia Department of Human Resources......B. J. Walker, Commissioner Division of Public

More information

2. Incidence, prevalence and duration of breastfeeding

2. Incidence, prevalence and duration of breastfeeding 2. Incidence, prevalence and duration of breastfeeding Key Findings Mothers in the UK are breastfeeding their babies for longer with one in three mothers still breastfeeding at six months in 2010 compared

More information